Paul J. Shami
( out of 82 reviews )

Paul J. Shami, MD

Languages spoken: English, French, Arabic

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Languages Spoken: English, French, Arabic

    Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Molecular Pharmaceutics at the University of Utah. He is Board Certified in Hematology and Medical Oncology. He started at the University of Utah in 1997. Dr. Shami oversees leukemia clinical trials at Huntsman Cancer Institute. His research also includes different strategies in drug discovery and drug development. Because of his expertise in the treatment of blood cancers, he serves or has served on the Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN).



    For questions regarding Dr. Shami's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 585-6906.

    Specialties

    Patient Rating

    5.0 /5
    ( out of 82 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    December 09, 2024
    HUNTSMAN CANCER CENTER

    One of the BEST Doctors I have ever worked with. He is kind, knowledgeable, and patient. He understands what we (his patients) are going through and is sensitive to our needs. He is very reasonable but also knows how much to give without compromising our health. I am SO grateful he is my doctor and is helping me through the fight of my life.

    November 23, 2024
    HUNTSMAN CANCER CENTER

    A great man

    November 23, 2024
    HUNTSMAN CANCER CENTER

    Dr. Paul Shami is the epitome of a professional and caring doctor. I have seen him for 12 years and he has always listened to my needs and communicated with me to alleviate my concerns and provide guidance during all of my health challenges. Now he is collaborating with another HCI doctor to ensure my surgery is safe and effective. Thank you, Dr. Shami, for all you have done for me. [NAME REMOVED]

    November 22, 2024
    HUNTSMAN CANCER CENTER

    A wonderful doctor. I would recommend him to anyone who is in need of a hematologist.

    November 20, 2024
    HUNTSMAN CANCER CENTER

    Dr. Paul Shami, Lexy, and Jordan listen to every request and include me in their decisions. Their immediate response to my messages on the portal is so very much appreciated.

    November 16, 2024
    HUNTSMAN CANCER CENTER

    Dr. Shami is through and explains things so I can understand. He inspires confidence with his quiet manner.

    November 04, 2024
    HUNTSMAN CANCER CENTER

    Was very patient and detailed things in a way I could understand. Took his time and seemed very interested in helping me through my process.

    October 22, 2024
    HUNTSMAN CANCER CENTER

    All appointments with Dr. Shami provide me with more information about my health. He cares deeply for his patients. Every question is answered right at my appointment so I leave with copious notes on how to take care of myself and what the needed next steps might be.He is so respected by everyone on his staff; that is easy to see.

    October 11, 2024
    HUNTSMAN CANCER CENTER

    He is incredibly kind, thorough and knowledgeable.

    See More Patient Comments

  • Languages Spoken: English, French, Arabic

    Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Molecular Pharmaceutics at the University of Utah. He is Board Certified in Hematology and Medical Oncology. He started at the University of Utah in 1997. Dr. Shami oversees leukemia clinical trials at Huntsman Cancer Institute. His research also includes different strategies in drug discovery and drug development. Because of his expertise in the treatment of blood cancers, he serves or has served on the Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN).



    For questions regarding Dr. Shami's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 585-6906.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Hematology & Hematologic Malignancies

    Education history

    Fellowship Hematology/Oncology - Duke University Medical Center Fellow
    Residency Internal Medicine - Duke University Medical Center Resident
    Internship Internal Medicine - Duke University Medical Center Intern
    Professional Medical Medicine - American University of Beirut M.D.
    Undergraduate Chemistry - American University of Beirut B.S.

    Selected Publications

    Journal Article

    1. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K (2023). Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(5), 503-513. (Read full article)
    2. Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola K, Luger S, Baer MR, Rizzieri DA, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad LE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey EH (2022). An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. Blood, 141(3), 295-308. (Read full article)
    3. Shami PJ (2023). Development of JS-K, a First-in-Class Arylated Diazeniumdiolate, for the Treatment of Cancer. Crit Rev Oncog, 28(1), 57-62. (Read full article)
    4. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C (2022). NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw, 20(2), 106-117. (Read full article)
    5. Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin TL (2021). Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers (Basel), 13(21). (Read full article)
    6. Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts J (2021). A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers (Basel), 13(16). (Read full article)
    7. Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Pea E, Elsawy M, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring W, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey EH (2020). Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 138(5), 387-400. (Read full article)
    8. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510. (Read full article)
    9. Sorror ML, Storer BE, Fathi AT, Brunner AM, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Pea E, Elsawy M, Adekola KUA, Luger S, Baer MR, Rizzieri D, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring WM, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum F, Estey EH (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood. (Read full article)
    10. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS (2021). NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw, 19(1), 16-27. (Read full article)
    11. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. (Read full article)
    12. Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud CN (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 61(8), 1965-1973. (Read full article)
    13. Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leuk Res, 87, 106262. (Read full article)
    14. Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang ES (2019). Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Adv, 3(13), 1939-1949. (Read full article)
    15. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, ODonnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, OCN, Hammond L, Ogba N (2019). Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(6), 721-749. (Read full article)
    16. Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kopeek J (2019). Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine, 16, 217-225. (Read full article)
    17. Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Pea E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH (2017). Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol, 3(12), 1675-1682. (Read full article)
    18. Zhang R, Yang J, Zhou Y, Shami PJ, Kopeek J (2016). N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia. Macromol Biosci, 16(1), 121-8. (Read full article)
    19. Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami PJ (2015). Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leuk Res, 39(8), 835-9. (Read full article)
    20. Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeek J (2015). A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics, 5(8), 834-46. (Read full article)
    21. Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami PJ (2015). Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K. Pharm Res, 32(4), 1395-406. (Read full article)
    22. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, ODonnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C, National comprehensive cancer network (2015). Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw, 13(3), 261-72. (Read full article)
    23. Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F (2015). REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol, 168(6), 796-805. (Read full article)
    24. Chu TW, Kosak KM, Shami PJ, Kopeek J (2014). Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells. Drug Deliv Transl Res, 4(5-6), 389-94. (Read full article)
    25. Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo W (2014). Targeting Glutathione S-transferase M4 in Ewing sarcoma. Front Pediatr, 2, 83. (Read full article)
    26. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Canc Netw, 12(8), 1113-21. (Read full article)
    27. ODonnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M, National Comprehensive Cancer Network (2013). Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw, 11(9), 1047-55. (Read full article)
    28. Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ (2013). Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles. J Pharm Pharmacol, 65(9), 1329-36. (Read full article)
    29. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, ODonnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M (2013). Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw, 11(7), 838-74. (Read full article)
    30. Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A (2013). Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide, 30, 17-25. (Read full article)
    31. Slomowitz SJ, Shami PJ (2012). Management of extramedullary leukemia as a presentation of acute myeloid leukemia. J Natl Compr Canc Netw, 10(9), 1165-9. (Read full article)
    32. ODonnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM (2012). NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw, 10(8), 984-1021. (Read full article)
    33. Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra JE (2012). Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. Bioorg Med Chem, 20(9), 3094-9. (Read full article)
    34. Shami PJ (2012). How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients. J Natl Compr Canc Netw, 10(1), 112-8; quiz 119. (Read full article)
    35. OBrien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F, National Comprehensive Cancer Network (2012). Chronic myelogenous leukemia. J Natl Compr Canc Netw, 10(1), 64-110. (Read full article)
    36. Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer LK (2012). Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class. For Immunopathol Dis Therap, 3(2), 91-95. (Read full article)
    37. Narayanan S, Shami PJ (2012). Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol, 81(1), 94-102. (Read full article)
    38. Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE (2011). Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs. J Med Chem, 54(22), 7751-8. (Read full article)
    39. ODonnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer Network (2011). Acute myeloid leukemia. J Natl Compr Canc Netw, 9(3), 280-317. (Read full article)
    40. Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK (2011). The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. J Pharmacol Exp Ther, 336(2), 313-20. (Read full article)
    41. OBrien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M (2011). NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw, 9 Suppl 2, S1-25. (Read full article)
    42. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, ODonnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw, 9(1), 30-56. (Read full article)
    43. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol, 28(4), 549-55. (Read full article)
    44. Edes K, Cassidy P, Shami PJ, Moos PJ (2010). JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. PLoS One, 5(1), e8786. (Read full article)
    45. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ (2010). JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol, 62(1), 145-51. (Read full article)
    46. Kiziltepe T, Anderson KC, Kutock JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ (2010). JS-K has Potent Anti-Angiogenic Activity In Vitro and Inhibits Tumor Angiogenesis in a Multiple Myeloma Model In Vivo. J Pharm Pharmacol, 62, 145-151.
    47. Kantarjian HM, Erba HP, Claxton D, Arellano M, Craig M, Douer D, Gabrilove J, Lyons R, Kovascovics T, Maris M, Petersdorf S, Shami PJ, Yaeger A, Eckert S, Abichandani R, Faderl S, On behalf of the CLASSIC II Investigators (2010). Phase II Study of Clofarabine Induction and Consolidation Therapy In Previously Untreated Older Adults With Acute Myelogenous Leukemia for Whom Conventional Induction Chemotherapy is Unlikely to be of Benefit Due to Unfavorable Baseline Risk Factors. J Clin Oncol, 28, 549-555.
    48. Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer LK (2009). JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leuk Res, 33(11), 1525-9. (Read full article)
    49. OBrien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M, National Comprehensive Cancer Network (2009). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw, 7(9), 984-1023. (Read full article)
    50. Liu J, Malavya S, Wang X, Saavedra JE, Keefer LK, Tokar E, Qu W, Waalkes MP, Shami PJ (2009). Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics, 94(1), 32-8. (Read full article)
    51. Saade M, Salamoun W, Tueni E, Shami PJ (2000). Who should be screened for hereditary breast cancer and what should be done with the information? J Med Liban, 47(5), 281-3. (Read full article)
    52. Shami PJ, Crews J (1995). Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. N C Med J, 56(12), 602-4. (Read full article)
    53. Ciaccia D, Quigley RL, Shami PJ, Grant JP (1994). A case of retrograde jejunoduodenal intussusception caused by a feeding gastrostomy tube. Nutr Clin Pract, 9(1), 18-21. (Read full article)

    Review

    1. Shami PJ, Deininger M (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. [Review]. Leukemia, 26(2), 214-24. (Read full article)
    2. Zeng J, Yang N, Li XM, Shami PJ, Zhan J (2010). 4'-O-Methylglycosylation of Curcumin by Beauveria bassiana. [Review]. Nat Prod Commun, 5, 77-80.

    Abstract

    1. Rudrapatna RK, Morley K, Kushner JP, Pierson AS, Shull CT, Shami PJ (2013). Phase I Trial of Low-Dose Oral Clofarabine in Myelodysplastic Syndromes Patients Who Have Failed Frontline Therapy [Abstract]. Proceedings of the 2013 meeting of the American Association for Cancer Research.
    2. Rudrapatna R, Kosak KM, Terrazas M, Kennedy TP, Shami PJ (2010). Development of Dithiocarbamate/Metal Complexes in Pluronic® micelles for the Treatment of Malignancies [Abstract]. Proceedings of the 2010 meeting of the American Association for Cancer Research, 5526.
    3. Kaur I, Kosak KM, Saavedra JE, Keefer LK, Kern Se, Shami PJ (2010). Cellular uptake and stability studies of the nitric oxide-generating pro-drug JS-K [Abstract]. Proceedings of the 2010 meeting of the American Association for Cancer Research, 2651.
    4. Maciag AE, Chakrapani H, Holland RJ, Morris JL, Shami PJ, Saavedra JE, Anderson LM, Keefer LK (2010). Diazeniumdiolate-based nitric oxide-releasing prodrugs kill lung adenocarcinoma in cells in culture and in vivo through alterations in cellular redox balance leading to mitochondrially-mediated apoptosis [Abstract]. Proceedings of the 2010 meeting of the American Association for Cancer Research, 4547.
    5. Kosak KM, Saavedra JE, Keefer LK, Shami PJ (2009). A Pluronic® micelle formuation increases the stability of the novel anti-cancer nitric oxide prodrug JS-K [Abstract]. Proceedings of the 2009 meeting of the American Association for Cancer Research, 643.

    Patent

    1. Kosak KM, Shami PJ (2008). In Vivo Use of Glutathione S-Transferase Activated Nitric Oxide Donors. U.S. Patent No. US patent 61/034,617.. Washington, D.C.:U.S. Patent and Trademark Office.
    2. Shami PJ (2002). In Vivo Use of Glutathione S-Transferase Activated Nitric Oxide Donors. U.S. Patent No. 8/404,665. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    Huntsman Cancer Institute News